Jæren Apotek Varhaug, Norway.
Epilepsy Behav. 2013 Oct;29(1):77-81. doi: 10.1016/j.yebeh.2013.06.031. Epub 2013 Aug 9.
The purpose of the present study was to describe the use of psychopharmacological drugs for the treatment of a stated or presumed psychiatric comorbid condition in patients with refractory epilepsy and discuss the clinical implications of such treatment. The study was a retrospective descriptive study in patients admitted to the National Center for Epilepsy in Norway based on medication described in medical records. The mean age was 40 years (range: 9-90), and the gender ratio was 56/44% female/male. Psychotropic drugs (antidepressants and antipsychotics) were used to a lower extent than in the general population in Norway. Drugs for ADHD were predominantly used in children. The prevalence of patients treated with psychiatric comedication was 13% (143 of 1139 patients). The patients used two to eight concomitant CNS-active drugs, which calls for the close monitoring of potential pharmacodynamic and pharmacokinetic interactions and should challenge clinicians to achieve a less complex pharmacotherapy. Psychiatric comorbidity is an important concern in patients with refractory epilepsy and may be undertreated.
本研究旨在描述在难治性癫痫患者中，针对明确或推测的精神共病状况使用精神药理学药物治疗的情况，并讨论这种治疗的临床意义。该研究是一项基于病历中描述的药物，对挪威国家癫痫中心收治的患者进行的回顾性描述性研究。患者的平均年龄为 40 岁（范围：9-90 岁），性别比例为 56/44%（女性/男性）。精神药物（抗抑郁药和抗精神病药）的使用比例低于挪威一般人群。ADHD 药物主要用于儿童。接受精神科药物治疗的患者比例为 13%（1139 例患者中有 143 例）。患者同时使用两种至八种 CNS 活性药物，这需要密切监测潜在的药效学和药代动力学相互作用，并应促使临床医生实现更简单的药物治疗。精神共病是难治性癫痫患者的一个重要关注点，可能治疗不足。
